Abstract
Background Acute kidney injury (AKI) is associated with poor outcomes in patients infected with SARS-CoV-2. Sepsis, direct injury to kidney cells by the virus, and severe systemic inflammation are mechanisms implicated in its development. We investigated the association between inflammatory markers (C-reactive protein, procalcitonin, D-dimer, lactate dehydrogenase, and ferritin) in patients infected with SARS-CoV-2 and the development of AKI.
Methods A prospective cohort study performed at the Civil Hospital (Dr. Juan I. Menchaca) Guadalajara, Mexico, included patients aged >18 years with a diagnosis of SARS-CoV-2 pneumonia confirmed by RT-PCR and who did or did not present with AKI (KDIGO) while hospitalized. Biomarkers of inflammation were recorded, and kidney function was estimated using the CKD-EPI formula.
Results 291 patients were included (68% men; mean age, 57 years). The incidence of AKI was 40.5% (118 patients); 21% developed stage 1 AKI, 6% developed stage 2 AKI, and 14% developed stage 3 AKI. The development of AKI was associated with phosphate higher (p = 0.002) (RR 1.39, CI 95% 1.13 – 1.72), high procalcitonin levels at hospital admission (p = 0.005) (RR 2.09, CI 95% 1.26-3.50), and high APACHE scores (p = 0.011) (RR 2.0, CI 95% 1.17-3.40). The survival analysis free of AKI according to procalcitonin levels and APACHE scores demonstrated a lower survival in patients with procalcitonin >0.5 ng/ml (p= 0.001) and APACHE >15 points (p = 0.004).
Conclusions phosphate, high procalcitonin levels, and APACHE scores >15 were predictors of AKI development in patients hospitalized with COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Hospital Civil de Guadalajara, and Dr. Juan I Menchaca gave ethical approval for this work. Registration number: 17CI14 039 116 COFEPRIS
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Most clinical data are restricted to protecting information from misuse. The data may be shared by the OPD, Hospital Civil de Guadalajara, and Dr. Juan I Menchaca (HCG-JIM) after approval from the Ethics Committee of the Institution. The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Abbreviations
- COVID-19
- Coronavirus 2019
- SAH
- Systemic arterial hypertension
- DM
- Diabetes mellitus
- AKI
- Acute kidney injury
- CRP
- C-reactive protein
- PCT
- Procalcitonin
- LDH
- Lactate dehydrogenase
- ALT
- Alanine aminotransferase
- SCr
- Serum creatinine
- CRRT
- Continuous Renal Replacement Therapy
- RT-PCR
- Reverse Transcriptase Polymerase Chain Reaction
- KDIGO
- Kidney Disease Improving Global Outcomes
- APACHE II
- Acute Physiology and Chronic Health Evaluation II
- SOFA
- Sequential Organ Failure Assessment
- eGFR
- Estimated glomerular filtration rate
- CKD
- Chronic Kidney Disease
- PaO2/FiO2
- Oxygen to fraction of inspired oxygen
- BMI
- Body Mass Index
- IMV
- Invasive mechanical ventilation
- ACEi
- Angiotensin-converting Enzyme Inhibitors
- ARBs
- Angiotensin receptor blockers
- NGAL
- Neutrophil gelatinase-associated lipocalin
- KIM-1
- Kidney injury molecule 1
